BioSpace News Archive

Endeavor BioMedicines announced that data from a completed Phase 2a clinical trial evaluating the completed Phase 2a clinical trial evaluating the company’s lead investigational candidate ENV-101 in patients with idiopathic pulmonary fibrosis (IPF) will be presented for the first time in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference. ATS 2024 will take place May 17-22, 2024, in San Diego.

Agilent Technologies Inc. announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately.

Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.

AbCellera, Viking Global Investors, and ArrowMark Partners announced that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies.

The Melanoma Research Alliance, the world’s leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.

Starlight Cardiovascular, Inc., a company developing pediatric cardiovascular medical devices, announced that it has been awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of its Pulmonary Flow Restrictor.

The U.S. Food and Drug Administration took important steps to advance the FDA’s regulatory process for intentional genomic alterations in animals.

SecondWave Systems, Inc., a pioneer in the emerging field of bio-ultrasonic medicine, today announced completion of a pilot clinical study evaluating its novel noninvasive ultrasound stimulation technology in the treatment of patients with rheumatoid arthritis (RA).

Affini-T Therapeutics, Inc. today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.

United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) with the clearance of its uMR Jupiter 5T MRI system.